Chemed president and CEO Kevin McNamara sells $1.03M in stock

Kevin J. McNamara, president and CEO of Chemed Corp. (NYSE:CHE), sold 2,000 shares of the company’s capital stock for a total value of $1,026,900 on September 28, 2026.

The shares were sold in multiple transactions at prices ranging from $510.93 to $515.12, with a weighted average price of $513.45 per share. Following this transaction, Mr. McNamara directly holds 66,418 shares of Chemed Corp. capital stock.The sale comes as Chemed trades at $513, with the stock up 18% over the past year. The company maintains a market capitalization of $6.68 billion and trades at a P/E ratio of 25.73. According to InvestingPro analysis, the stock appears undervalued relative to its Fair Value, placing it among opportunities on the Most Undervalued stocks list. An InvestingPro tip highlights that Chemed has maintained dividend payments for 56 consecutive years, with 11 additional exclusive tips available to subscribers.

Mr. McNamara serves as president and CEO, and is also a director of Chemed Corp.

In other recent news, Chemed Corporation reported second-quarter results that surpassed Wall Street expectations, driven by robust growth in its hospice unit, VITAS, and stable performance from Roto-Rooter. The company posted adjusted earnings of $6.06 per share on revenue of $673.25 million, exceeding analysts’ projections of $5.60 per share and $665.04 million in revenue. This represents a 41.9% increase in adjusted earnings per share from the previous year, highlighting improved operating leverage. Additionally, UBS has initiated coverage on Chemed with a buy rating, setting a price target of $650.00. The firm anticipates low double-digit adjusted earnings per share growth, projecting 19% growth in 2026 and 10% growth in both 2027 and 2028. These developments reflect a positive outlook for the company’s future performance.